1193779-36-0

Basic information

• Product Name: 4-Chloro Bupropion FuMarate
• Synonyms: 4-Chloro Bupropion FuMarate;1-(3,4-Dichlorophenyl)-2-[(1,1-diMethylethyl)aMino]-1-propanone (2E)-2-Butenedioate;4-Chloro Bupropion-d9 Fumarate4-Chloro Bupropion Fumarate
• CAS NO: 1193779-36-0
• Molecular Formula: C₄H₄O₄*C₁₃H₁₇Cl₂NO
• Molecular Weight: 390.25834
• Product Categories: Amines;Aromatics;Intermediates & Fine Chemicals;Pharmaceuticals;Amines, Aromatics, Pharmaceuticals, Intermediates & Fine Chemicals
• Mol File: 1193779-36-0.mol

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 4-Chloro Bupropion FuMarate(CAS DataBase Reference)
• NIST Chemistry Reference: 4-Chloro Bupropion FuMarate(1193779-36-0)
• EPA Substance Registry System: 4-Chloro Bupropion FuMarate(1193779-36-0)

Safety Data

• Hazardous Substances Data: 1193779-36-0(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
4-Chloro Bupropion FuMarate is used as an indirect dopamine agonist for the treatment of addiction to drugs such as cocaine, methamphetamine, and nicotine. Its application in this context is due to its ability to modulate dopamine levels in the brain, which is essential for managing the symptoms of addiction and withdrawal.
Used in Addiction Treatment:
4-Chloro Bupropion FuMarate is employed as a therapeutic agent in the treatment of drug addiction. It helps in reducing cravings and withdrawal symptoms, making it easier for patients to overcome their addiction to harmful substances. Its effectiveness in this application is attributed to its indirect agonist action on dopamine receptors, which are known to be involved in the reward and reinforcement pathways associated with drug addiction.
Used in Research and Development:
In addition to its clinical applications, 4-Chloro Bupropion FuMarate is also used in research and development for the study of dopaminergic systems and the development of new pharmacotherapies for addiction treatment. Its unique chemical structure and pharmacological properties make it a valuable tool for understanding the mechanisms underlying drug addiction and for designing novel therapeutic strategies to combat this global health issue.

Upstream product

• 110-17-8 (2E)-but-2-enedioic acid 

Relevant articles and documents

MONOAM1NE REUPTAKE INHIBITORS

The invention provides bupropion analogue compounds capable of inhibiting the reuptake of one or more monoamines. The compounds may selectively bind to one or more monoamine transporters, including those for dopamine, norepinephrine,and serotonin. Such compounds may be used to treat conditions that are responsive to inhibition of the reuptake of monoamines, including addiction, depression, and obesity

Synthesis and biological evaluation of bupropion analogues as potential pharmacotherapies for cocaine addiction

A series of bupropion (1a) analogues (1b-1ff) were synthesized, and their in vitro and in vivo pharmacological properties evaluated with the goal of developing a 1a analogue that had better properties for treating addictions. Their in vitro pharmacological properties were examined by [3H] dopamine ([3H]DA), [3H]serotonin ([3H]5HT), and [3H]norepinephrine ([3H]NE) uptake inhibition studies, and by binding studies at the dopamine, serotonin, and norepinephrine transporters using [125I]RTI-55 in cloned transporters. Several analogues showed increased [3H]DAuptake inhibition with reduced or little change in [3H]5HT and [3H]NE uptake inhibition relative to bupropion. Thirty-five analogues were evaluated in a 1 h locomotor activity observation test and 32 in an 8 h locomotor activity observation test and compared to the locomotor activity of cocaine. Twenty-four analogues were evaluated for generalization to cocaine drug discrimination after i.p. administration, and twelve analogues were tested in a time course cocaine discrimination study using oral administration. 2-(N-Cyclopropylamino)-3- chloropropiophenone (1x) had the most favorable in vitro efficacy and in vivo pharmacological profile for an indirect dopamine agonist pharmacotherapy for treating cocaine, methamphetamine, nicotine, and other drugs of abuse addiction. 2009 American Chemical Society.